C. Bane

Higher risk breast screening: cancer detection rates, recall rates, and attendance rates in Northern Ireland.

E. Gibson, G. Rocks, G. Gracey, 2019, Clinical radiology.

Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).

V. Roy, B. Laplant, F. Palmieri, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of weekly nab ( nanoparticle albumin-bound )-paclitaxel ( nab-paclitaxel ) ( Abraxane ) in combination with gemcitabine in patients with metastatic breast cancer ( N 0531 )

V. Roy, B. Laplant, F. Palmieri, 2009 .

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

A phase I/II trial of vorinostat (SAHA) in combination with rituximab‐CHOP in patients with newly diagnosed advanced stage diffuse large B‐cell lymphoma (DLBCL): SWOG S0806

Sonali M. Smith, J. Friedberg, L. Rimsza, 2015, American journal of hematology.

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

J. Wolchok, M. Atkins, J. Sosman, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609

V. Sondak, J. Kirkwood, F. Hodi, 2022, Quality of Life Research.

Rheumatologists' judgements about the efficacy of anti-TNF therapy in two neighbouring regions.

M. Dempster, F. Kee, N. Sheehy, 2005, Rheumatology.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

J. Sosman, A. Ribas, P. Scumpia, 2023, Nature Medicine.